Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;6(3):221-9.
doi: 10.3978/j.issn.2072-1439.2013.11.12.

Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis

Kai-Xiong Liu  1 , Bing Xu  1 , Jie Wang  1 , Jing Zhang  1 , Hai-Bo Ding  1 , Felinda Ariani  1 , Jie-Ming Qu  1 , Qi-Chang Lin  1
Affiliations

Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis

Kai-Xiong Liu et al. J Thorac Dis. 2014 Mar.

Abstract

Purpose: To evaluate the efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (AECOPD).

Methods: We searched PubMed, EMBASE, and the Web of Science for relevant studies. Two reviewers extracted data and reviewed the quality of the studies independently. The primary outcome was clinical success at early follow-up. Study-level data were pooled using a random-effects model when I(2) was >50% or a fixed-effects model when I(2) was <50%.

Results: Eleven randomized controlled studies were considered. There was no difference between moxifloxacin and comparator agents with regard to treatment success in intention-to-treat (ITT) [odds ratio (OR) =1.18, 95% confidence interval (CI) 0.98-1.42], clinically evaluable (CE) (OR 1.13, 95% CI, 0.93-1.37) patients, or adverse effects in general (OR 1.00, 95% CI, 0.86-1.17). Moxifloxacin was associated with better microbiological success (OR 1.45; 95% CI, 1.14-1.85).

Conclusions: Moxifloxacin was as clinically equivalent and bacteriologically superior to the antibiotic regimens routinely used in patients with AECB and AECOPD. Moxifloxacin therapy may be a promising and safe alternative to empirical treatment for AECB and AECOPD.

Keywords: Moxifloxacin; chronic bronchitis; chronic obstructive pulmonary disease (COPD); meta-analysis; systematic review.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of study selection.
Figure 2
Figure 2
Clinical success in the ITT patients with AECB in RCTs comparing moxifloxacin versus other antimicrobial treatment.
Figure 3
Figure 3
Clinical success in the CE patients with AECB in RCTs comparing moxifloxacin versus other antimicrobial treatment.
Figure 4
Figure 4
Bacteriological success in patients with AECB in RCTs comparing moxifloxacin versus other antimicrobial treatment.
Figure 5
Figure 5
Drug-related adverse events in patients with AECB in RCTs comparing moxifloxacin versus other antimicrobial treatment.
Figure 6
Figure 6
Funnel plot showing the possibility of a small publication bias.
See this image and copyright information in PMC

References

    1. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22 - PubMed
    1. Anzueto A.Impact of exacerbations on COPD. Eur Respir Rev 2010;19:113-8 - PMC - PubMed
    1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-73 - PubMed
    1. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204 - PubMed
    1. Sethi S.Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000;117:380S-5S - PubMed